healio.com
Q&A: IBD wearable alerts patients ‘in real time’ about impending disease flares
A noninvasive wearable that tracks inflammation markers could let people with IBD and their clinicians detect rising disease activity earlier and potentially act before symptoms develop. This may make monitoring less burdensome than frequent blood or stool tests and help personalize follow-up testing.
Adults with IBD (Crohn’s disease or ulcerative colitis), patients on biologic therapy, clinicians who manage IBD, and researchers developing biomarker-based monitoring tools.
What To Know
What To Know Healio reports on a wearable called IBD Aware (EnLiSense) that measures inflammation-related biomarkers in sweat — including CRP, fecal-calprotectin analogs in sweat, TNF‑α and IL‑6 — to track disease activity and alert patients and clinicians in near real time about rising inflammation that may precede a flare.
The device developers say it could be prescribed by clinicians (anticipated FDA 510(k) Class II pathway) and used either periodically or continuously depending on disease state and clinical judgment. The platform’s goal is to provide a temporal profile of biochemical signals to guide remote monitoring and decisions about follow-up labs or imaging.
The interview highlights potential patient benefits: earlier biochemical detection of rising inflammation before symptoms, longitudinal logging of actionable data, and the possibility of reducing unnecessary or inconvenient testing by targeting follow-up when biomarkers change.
Next steps and limitations discussed in the article include the need for regulatory review, tailoring wear schedules to individuals, and that timing of when a flare will occur relative to biomarker changes will vary between patients.
This piece is an interview/feature about a device in development; it describes intended biomarkers, potential uses, and regulatory plans but does not present peer-reviewed clinical trial data demonstrating accuracy, clinical outcomes, or FDA clearance. Timing and clinical utility (how far in advance flares can be predicted) are described as variable and patient-specific.
